The Quantellect read.As of Nov 19, 2026, 5 active firms cover Sensei Biotherapeutics Inc: 5 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $50.00 to $55.00, so the covering firms are broadly aligned. The average target of $53.33 sits 512% above the current $8.72. The rating mix has held broadly steady over recent months.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 active firms
Buy
Strong Buy00%
Buy5100%
Neutral00%
Sell00%
Strong Sell00%
Based on 5 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$53.33
+511.6% upside
Average target across 3 active firms as of Nov 19, 2026 vs $8.72 current
Highest Target$55.00
Average Target$53.33
Lowest Target$50.00
Detailed analyst forecasts for SNSE
Showing 1–4 of 4 named analysts shown · 5 active firms in the rating projection
As of Nov 19, 2026, 5 of 5 active firms rate SNSE a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
Top analysts covering Sensei Biotherapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SNSE.
#1
SL
Sudan Loganathan
Stephens & Co. · Rank #80
Buy
$35.00+301.4% to target
Overall win rate
47%
+ Follow
#2
Francois Brisebois
Oppenheimer · Rank #282
Buy
$4.00-54.1% to target
Overall win rate
40%
+ Follow
#3
SS
Samantha Semenkow
Citigroup · Rank #333
Buy
$55.00+530.7% to target
Overall win rate
41%
+ Follow
#4
Li Watsek
Cantor Fitzgerald · Rank #357
Buy
No targeton SNSE
Overall win rate
38%
+ Follow
#5
Joseph Pantginis
HC Wainwright & Co. · Rank #373
Buy
$30.00+244.0% to target
Overall win rate
34%
+ Follow
SNSE stock forecast FAQ
What is SNSE's average 12-month price target?+
The 3 active firms with a live target average $53.33 for Sensei Biotherapeutics Inc over the next 12 months, ranging from a $55.00 high to a $50.00 low, as of Nov 19, 2026.
Is SNSE stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 5 active firms as of Nov 19, 2026, 5 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for SNSE?+
The Street-high target is $55.00 (BTIG), and the Street-low is $50.00 (LUCID CAPITAL MARKETS). The average of all 3 active-firm targets is $53.33.
How many active Wall Street firms cover SNSE?+
5 active firms have a recognized rating on Sensei Biotherapeutics Inc as of Nov 19, 2026, and 3 active firms carry a live 12-month price target.
Who is the most accurate analyst covering SNSE?+
Among analysts who currently cover SNSE, Sudan Loganathan of Stephens & Co. has the strongest overall Quantellect track record (Rank #80). Their current call is Buy with a $35.00 target.
Have analysts been upgrading or downgrading SNSE lately?+
As of Nov 19, 2026, 5 of 5 active firms rate SNSE a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SNSE calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.